276 related articles for article (PubMed ID: 23590397)
21. Pharmacokinetic and pharmacodynamic profile of ceftobiprole.
Lodise TP; Patel N; Renaud-Mutart A; Gorodecky E; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2008 May; 61(1):96-102. PubMed ID: 18384996
[TBL] [Abstract][Full Text] [Related]
22. Current and Future Considerations for the Treatment of Hospital-Acquired Pneumonia.
Montravers P; Harpan A; Guivarch E
Adv Ther; 2016 Feb; 33(2):151-66. PubMed ID: 26861846
[TBL] [Abstract][Full Text] [Related]
23. Microbiology of ventilator-associated pneumonia compared with that of hospital-acquired pneumonia.
Weber DJ; Rutala WA; Sickbert-Bennett EE; Samsa GP; Brown V; Niederman MS
Infect Control Hosp Epidemiol; 2007 Jul; 28(7):825-31. PubMed ID: 17564985
[TBL] [Abstract][Full Text] [Related]
24. Antibiotic resistance in nosocomial respiratory infections.
Denys GA; Relich RF
Clin Lab Med; 2014 Jun; 34(2):257-70. PubMed ID: 24856527
[TBL] [Abstract][Full Text] [Related]
25. Causative agents and resistance among hospital-acquired and ventilator-associated pneumonia patients at Srinagarind Hospital, northeastern Thailand.
Reechaipichitkul W; Phondongnok S; Bourpoern J; Chaimanee P
Southeast Asian J Trop Med Public Health; 2013 May; 44(3):490-502. PubMed ID: 24050082
[TBL] [Abstract][Full Text] [Related]
26. Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials.
Scheeren TWL; Welte T; Saulay M; Engelhardt M; Santerre-Henriksen A; Hamed K
BMC Infect Dis; 2019 Feb; 19(1):195. PubMed ID: 30808293
[TBL] [Abstract][Full Text] [Related]
27. Ceftobiprole: A novel, broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Dauner DG; Nelson RE; Taketa DC
Am J Health Syst Pharm; 2010 Jun; 67(12):983-93. PubMed ID: 20516468
[TBL] [Abstract][Full Text] [Related]
28. Early-onset pneumonia after liver transplantation: microbiological findings and therapeutic consequences.
Weiss E; Dahmani S; Bert F; Janny S; Sommacale D; Dondero F; Francoz C; Belghiti J; Mantz J; Paugam-Burtz C
Liver Transpl; 2010 Oct; 16(10):1178-85. PubMed ID: 20879016
[TBL] [Abstract][Full Text] [Related]
29. Challenges in the design and conduct of clinical trials for hospital-acquired pneumonia and ventilator-associated pneumonia: an industry perspective.
Barriere SL
Clin Infect Dis; 2010 Aug; 51 Suppl 1():S4-9. PubMed ID: 20597670
[TBL] [Abstract][Full Text] [Related]
30. A Phase 3, Randomized, Investigator-blinded Trial Comparing Ceftobiprole With a Standard-of-care Cephalosporin, With or Without Vancomycin, for the Treatment of Pneumonia in Pediatric Patients.
Bosheva M; Gujabidze R; Károly É; Nemeth A; Saulay M; Smart JI; Hamed KA
Pediatr Infect Dis J; 2021 Jun; 40(6):e222-e229. PubMed ID: 33480665
[TBL] [Abstract][Full Text] [Related]
31. Registration trials of antibacterial drugs for the treatment of nosocomial pneumonia.
Sorbello A; Komo S; Valappil T; Nambiar S
Clin Infect Dis; 2010 Aug; 51 Suppl 1():S36-41. PubMed ID: 20597669
[TBL] [Abstract][Full Text] [Related]
32. Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia.
Rello J; Ulldemolins M; Lisboa T; Koulenti D; Mañez R; Martin-Loeches I; De Waele JJ; Putensen C; Guven M; Deja M; Diaz E;
Eur Respir J; 2011 Jun; 37(6):1332-9. PubMed ID: 20847075
[TBL] [Abstract][Full Text] [Related]
33. Review of recent clinical trials of hospital-acquired pneumonia and ventilator-associated pneumonia: a perspective from academia.
Kollef MH
Clin Infect Dis; 2010 Aug; 51 Suppl 1():S29-35. PubMed ID: 20597668
[TBL] [Abstract][Full Text] [Related]
34. Other therapeutic modalities and practices: implications for clinical trials of hospital-acquired or ventilator-associated pneumonia.
Chastre J; Luyt CE
Clin Infect Dis; 2010 Aug; 51 Suppl 1():S54-8. PubMed ID: 20597673
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline.
Bhavnani SM; Rubino CM; Hammel JP; Forrest A; Dartois N; Cooper CA; Korth-Bradley J; Ambrose PG
Antimicrob Agents Chemother; 2012 Feb; 56(2):1065-72. PubMed ID: 22143524
[TBL] [Abstract][Full Text] [Related]
36. Ceftobiprole medocaril for the treatment of pneumonia.
Hsu WH; Hsu CK; Lai CC
Expert Rev Anti Infect Ther; 2023 Jun; 21(6):551-563. PubMed ID: 37042813
[TBL] [Abstract][Full Text] [Related]
37. Emerging drugs for nosocomial pneumonia.
Liapikou A; Torres A
Expert Opin Emerg Drugs; 2016 Sep; 21(3):331-41. PubMed ID: 27347712
[TBL] [Abstract][Full Text] [Related]
38. New antibiotics for healthcare-associated pneumonia.
Neuner EA; Ritchie DJ; Micek ST
Semin Respir Crit Care Med; 2009 Feb; 30(1):92-101. PubMed ID: 19199191
[TBL] [Abstract][Full Text] [Related]
39. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Jorgenson MR; DePestel DD; Carver PL
Ann Pharmacother; 2011 Nov; 45(11):1384-98. PubMed ID: 22009993
[TBL] [Abstract][Full Text] [Related]
40. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
